title: Combination of BCL11A siRNA with vincristine increases the apoptosis of SUDHL6 cells.
abstract: BACKGROUND
  B cell chronic lymphocytic leukemia/lymphoma 11 A (BCL11A) is associated with human B cell malignancy initiation. Our previous study has shown that downregulation of BCL11A mRNA by small interfering RNA (siRNA) is capable of inducing apoptosis in the SUDHL6 cell line. To further explore the effects of BCL11A siRNA on the enhanced cytotoxicity of a chemotherapeutic drug, we investigated the effects of BCL11A siRNA combined with vincristine (VCR) on SUDHL6 cell proliferation and apoptosis.
  
  
  METHODS
  Chemically synthesized BCL11A siRNA was transfected into SUDHL6 cells using the HiPerFect Transfection Reagent in combination with VCR. Cell proliferation was measured by the CCK8 assay. The morphology of apoptotic cells was observed with Hoechst 33258 staining. The rate of cell apoptosis was determined by annexin V-fluorescein isothiocyanate/propidium iodide double staining using fluorescence-activated cell sorting (FACS) analysis.
  
  
  RESULTS
  After BCL11A siRNA plus VCR treatment, cell proliferation was significantly decreased in comparison with VCR or BCL11A siRNA treatment alone and negative control siRNA plus VCR treatment (P <0.05). The apoptotic rate of BCL11A siRNA plus VCR treated cells was significantly increased compared with BCL11A siRNA and VCR treatment alone and negative control siRNA plus VCR treatment (P <0.05).
  
  
  CONCLUSIONS
  The combination of BCL11A siRNA and VCR increases apoptosis in SUDHL6 cells. Our study implies that BCL11A siRNA in combination with VCR may be a useful approach for improving effective treatment for B cell lymphoma.
authors: Institute of Hematology, Medical College, Jinan University, No, 601, West Huangpu Road, Guangzhou, Tianhe District 510632, PR China. thedm@jnu.edu.cn.
authors: Dongmei
authors: D
authors: He
authors: Hong
authors: H
authors: Wu
authors: Li
authors: L
authors: Ding
authors: Yangqiu
authors: Y
authors: Li
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage*; D017209:Apoptosis / Q000187:drug effects*; D002352:Carrier Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D045744:Cell Line, Tumor; D015316:Genetic Therapy / Q000379:methods; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse; D009687:Nuclear Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D034741:RNA, Small Interfering / Q000008:administration & dosage*; D012097:Repressor Proteins; D014162:Transfection; D014750:Vincristine / Q000008:administration & dosage*
chemical_list: D000970:Antineoplastic Agents; C486563:BCL11A protein, human; D002352:Carrier Proteins; D009687:Nuclear Proteins; D034741:RNA, Small Interfering; D012097:Repressor Proteins; D014750:Vincristine